Prostate cancer
Conditions
Interventions
Single:Administration of Study drug ZA-001
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
Male
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years. (2) Have progressive mCRPC with histologically or cytologically confirmed adenocarcinoma of the prostate, and have documented PSA and/or radiographic progression. (3) have Ga 68 PSMA-11 PET/CT PSMA positive lesions. (4) ECOG 0 to 1. (5) Previous castration treatment and keep castration with testosterone level. (6) Adequate hematological and organ function.
Exclusion criteria
Exclusion criteria: (1) Less than 4 weeks since last myelosuppressive therapy; (2) With active or uncontrolled infection; (3) Have used any other investigational drugs within 4 weeks or 5 half-lives (whichever is shorter) prior to the start of the study treatment, or have used any investigational medical devices within 4 weeks prior to the start of the study treatment. (4) Previously known to have a history of allergy, hypersensitivity, or intolerance to radioactive drugs; or known to be allergic to ethanol. (5) have a pregnant partner or are capable of fathering a child and who are unwilling to take precautions to prevent potential harm to the fetus or prevent pregnancy during and for 90 days after discontinuation of study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biodistribution;The incidence and severity of adverse events (AEs); | — |
Countries
China
Contacts
Public ContactRong Tian
Department of Nuclear Medicine, West China Hospital of Sichuan University
Outcome results
None listed